IP Library Granted Patent US 11,192,852
Granted Patent B2
US 11,192,852 · App. 16/701,585 · Granted Dec 7, 2021

Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Inventors: Eric Anderson (Southlake, TX); Gary L. Bolton (Ann Arbor, MI); Bradley Caprathe (Livonia, MI); Xin Jiang (Coppell, TX); Chitase Lee (Ann Arbor, MI); William H. Roark (Ann Arbor, MI); Melean Visnick (Irving, TX)
Assignee: REATA PHARMACEUTICALS, INC.
C07C255/47C07D231/54C07D239/70C07D401/04C07D403/04C07D413/04C07D417/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,192,852
App. No.
16/701,585
Granted
Dec 7, 2021
Kind
B2
Abstract

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Claims (37)

1. A method of making a compound of formula (VIX):

or a pharmaceutically acceptable salt or tautomer thereof, wherein:

n is 1 or 2;

X is —CN, —CF 3 , or —C(O)R a , wherein R a is —OH, alkoxy (C≤6) , alkylamino (C≤6) , dialkylamino (C≤6) , or —NHS(O) 2 -alkyl (C1-4) ;

R 1 and R 2 are each independently hydrogen, hydroxy, halo, or amino; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , hetero-aryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) , alkoxy (C≤12) , aryloxy (C≤12) , aralkoxy (C≤12) , heteroaryloxy (C≤12) , acyloxy (C≤12) , alkylamino (C≤12) , dialkylamino (C≤12) , arylamino (C≤12) , aralkylamino (C≤12) , heteroaryl-amino (C≤12) , amido (C≤12) , or a substituted version of any of these groups; or

R 1 and R 2 are taken together and are alkanediyl (C≤12) , alkenediyl (C≤12) , alkoxydiyl (C≤12) , alkylaminodiyl (C≤12) , or a substituted version of any of these groups;

R 3 is absent, hydrogen; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) or a substituted version of any of these groups; or R 3 is taken together with R 4 as provided below; provided that R 3 is absent when and only when the atom to which it is bound forms part of a double bond;

R 4 is hydrogen, hydroxy, amino, halo, cyano, or oxo; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) , alkoxy (C≤12) , aryloxy (C≤12) , aralkoxy (C≤12) , heteroaryloxy (C≤12) , acyloxy (C≤12) , alkylamino (C≤12) , dialkylamino (C≤12) , arylamino (C≤12) , aralkylamino (C≤12) , heteroarylamino (C≤12) , amido (C≤12) , or a substituted version of any of these groups; or R 4 is taken together with either R 3 or R 5 as provided below;

R 5 is absent, hydrogen; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) or a substituted version of any of these groups; or R 5 is taken together with R 4 as provided below; provided that R 5 is absent when and only when the atom to which it is bound forms part of a double bond; and

R 6 is hydrogen, hydroxy, amino, halo, cyano, or oxo; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) , alkoxy (C≤12) , aryloxy (C≤12) , aralkoxy (C≤12) , heteroaryloxy (C≤12) , acyloxy (C≤12) , alkylamino (C≤12) , dialkylamino (C≤12) , arylamino (C≤12) , aralkylamino (C≤12) , heteroarylamino (C≤12) , amido (C≤12) , or a substituted version of any of these groups;

provided that when R 3 and R 4 are taken together, the compound is further defined by formula Ic:

wherein R 7 is hydrogen, hydroxy, amino, halo, or cyano; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) , alkoxy (C≤12) , aryloxy (C≤12) , aralkoxy (C≤12) , heteroaryloxy (C≤12) , acyloxy (C≤12) , alkylamino (C≤12) , dialkylamino (C≤12) , arylamino (C≤12) , aralkylamino (C≤12) , heteroarylamino (C≤12) , amido (C≤12) , or a substituted version of any of these groups; or

provided that when R 4 and R 5 are taken together, the compound is further defined by formula Id:

wherein R 8 is hydrogen, hydroxy, amino, halo, or cyano; or alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heterocycloalkyl (C≤12) , acyl (C≤12) , alkoxy (C≤12) , aryloxy (C≤12) , aralkoxy (C≤12) , heteroaryloxy (C≤12) , acyloxy (C≤12) , alkylamino (C≤12) , dialkylamino (C≤12) , arylamino (C≤12) , aralkylamino (C≤12) , heteroarylamino (C≤12) , amido (C≤12) , or a substituted version of any of these groups;

comprising obtaining a compound of formula (VIXa):

or a salt or tautomer thereof, wherein the variables are defined hereinabove; and

reacting the compound of formula (VIXa) under conditions suitable to form the compound of formula (VIX).

2. The method of claim 1 , wherein n is 2.

3. The method of claim 1 , wherein X is —CN.

4. The method of claim 1 , wherein R 1 and R 2 are each independently hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , aryl (C≤8) , or aralkyl (C≤8) ; or R 1 and R 2 are taken together and are alkanediyl (C≤8) .

5. The method of claim 4 , wherein R 1 is methyl and R 2 is hydrogen.

6. The method of claim 1 , wherein R 3 is absent.

7. The method of claim 1 , wherein R 3 is hydrogen; or alkyl (C≤8) , aryl (C≤8) , acyl (C≤8) , or a substituted version of any of these groups.

8. The method of claim 1 , wherein R 4 is hydrogen, oxo, or heteroaryl (C≤8) ; or alkyl (C≤8) , aryl (C≤8) , acyl (C≤8) , alkoxy (C≤8) or a substituted version of any of these groups.

9. The method of claim 1 , wherein R 5 is absent.

10. The method of claim 1 , wherein R 5 is hydrogen; or alkyl (C≤8) , aryl (C≤8) , acyl (C≤8) , or a substituted version of any of these groups.

11. The method of claim 1 , wherein R 6 is hydrogen, cyano, halo, amido (C≤8) , alkynyl (C≤8) , acyl (C≤8) , or alkoxy (C≤8) ; or alkyl (C≤6) , aryl (C≤8) , heteroaryl (C≤8) , aralkyl (C≤12) , or a substituted version of any one of these groups.

12. The method of claim 11 , wherein R 6 is substituted aryl (C≤8) .

13. The method of claim 12 , wherein R 6 is chlorophenyl, fluorophenyl, or methoxyphenyl.

14. The method of claim 1 , wherein carbon atom 10 is in the S configuration and carbon atom 5 is in the R configuration.

15. The method of claim 1 , wherein the compound is further defined as:

16. The method of claim 1 , wherein the conditions comprise contacting the compound of formula (VIXa) with an oxidizing agent.

17. The method of claim 16 , wherein the oxidizing agent is Br 2 , pyridinium bromide perbromide, 1,3-dibromo-5,5-dimethylhydantoin, or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

18. The method of claim 1 , wherein the conditions comprise contacting the compound of formula (VIXa) with an oxidizing agent to form an intermediate and contacting the intermediate with a base.

19. The method of claim 18 , wherein the oxidizing agent is Br 2 , pyridinium bromide perbromide, 1,3-dibromo-5,5-dimethylhydantoin, or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

20. The method of claim 18 , wherein the base is pyridine.

21. The method of claim 1 , wherein R 4 is hydrogen, oxo, or heteroaryl (C≤12) ; or alkyl (C≤12) , aryl (C≤12) , acyl (C≤12) , alkoxy (C≤12) or a substituted version of any of these groups.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2019
From: ANDERSON, ERIC; JIANG, XIN; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 051162/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2019
From: AAPHARMASYN LLC
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 051162/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2019
From: BOLTON, GARY L.; CAPRATHE, BRADLEY; LEE, CHITASE; ROARK, WILLIAM H.
To: AAPHARMASYN L.L.C
Reel/Frame 051162/0694 →
Continuity (6)
Continuation 15861758 · Jan 4, 2018
Continuation 14877974 · Oct 8, 2015
Continuation 13939818 · Jul 11, 2013
Continuation 13330378 · Dec 19, 2011
Provisional Application 61424601 · Dec 17, 2010
Related Publication 20200207706A1 · Jul 2, 2020
Cited By (1)
US 12,195,443